The disputed invention is closely related to the research and development of C-RAD's image detector called 'Gemini'. This product is not commercialized and all development and operations around this product ceased in
About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD. Inspiring excellence in cancer treatment.
For more information on C-RAD, please visit http://www.c-rad.com
For further information:
This information is information that
https://news.cision.com/c-rad/r/the-patent-and-market-court-of-appeal-issues-judgement-confirming-c-rad-s-entitlement-to-beamocular-,c3332341
https://mb.cision.com/Main/13008/3332341/1406450.pdf
(c) 2021 Cision. All rights reserved., source